2023-11-04T22:44:10+03:00[Europe/Moscow] en true <p>pregnancy, renal artery stenosis, previous angioedema </p>, <p>continue titrating to max tolerated dose </p>, <p>reduce dose and repeat creatinine every 1-2 weeks until &lt;30% above baseline</p>, <p>discontinue ACEi/ARB</p>, <p>slow CKD progression, decreased advancement to ESRD (dialysis/transplant), reduce CV events, decrease albuminuria </p>, <p>canagliflozin </p>, <p>&gt;=30ml/min </p>, <p>&gt;=25ml/min </p>, <p>&gt;=20 ml/min</p>, <p>albuminuria (&gt;200-300), T2DM, HF</p>, <p>hx of severe genital infections, significant UTI risk, hx/risk of ketoacidosis, on immunosuppressants, hypovolemia/hypotension</p>, <p>GFR; SCr </p>, <p>T2DM + CKD + albuminuria; already on max ACEi/ARB</p>, <p>eGFR, potassium</p>, <p>&gt;=25% decrease in GFR or increased albuminuria </p>, <p>a</p>, <p>b</p>, <p>c</p>, <p>d</p>, <p>educate patients/improve utilization of 1st line options, address barriers to utilization of highest quality meds </p>, <p>NSAIDs, herbals </p>, <p>flu, hep b, pneumococcal</p>, <p>progression to ESKD, proteinuria/albuminuria, CV risk </p> flashcards
CKD Therapeutics (Pt.2)

CKD Therapeutics (Pt.2)

Customize
collection saved
Share
Long Term Learning Spaced Repetition
Add to Long Term Learning Desk
Fast learning Repeat this set of flashcards
Preview Test Spell
Play
Match
Review

  • pregnancy, renal artery stenosis, previous angioedema

    What are contraindications of ACEi/ARBs? (3)

  • continue titrating to max tolerated dose

    What do we do to the dose of the ACEi/ARB if there is a <30% increase in SCr?

  • reduce dose and repeat creatinine every 1-2 weeks until <30% above baseline

    What do we do to the dose of the ACEi/ARB if there is a 31-50% increase in SCr?

  • discontinue ACEi/ARB

    What do we do to the dose of the ACEi/ARB if there is a >50% increase in SCr?

  • slow CKD progression, decreased advancement to ESRD (dialysis/transplant), reduce CV events, decrease albuminuria

    How have SGLT2-inhibitors been proven to help in CKD patients? (4)

  • canagliflozin

    Which SGLT2 inhibitor is indicated for patients with T2DM ONLY?

  • >=30ml/min

    What is the eGFR cutoff for starting Canagliflozin?

  • >=25ml/min

    What is the eGFR cutoff for starting Dapagliflozin?

  • >=20 ml/min

    What is the eGFR cutoff for starting Empagliflozin?

  • albuminuria (>200-300), T2DM, HF

    What are the high priority patients for SGLT2 selection? (3)

  • hx of severe genital infections, significant UTI risk, hx/risk of ketoacidosis, on immunosuppressants, hypovolemia/hypotension

    Who should we consider avoiding the use of SGLT2 inhibitors in? (5)

  • GFR; SCr

    When starting a patient on an SGLT2 inhibitor, we can expect a slight

    decrease in _________ and increase in ________.

  • T2DM + CKD + albuminuria; already on max ACEi/ARB

    When do we consider adding Finerenone to a patient's medication regimen?

  • eGFR, potassium

    What is Finerenone dosing based off of? (2)

  • >=25% decrease in GFR or increased albuminuria

    CKD progression is defined as what?

  • a

    Which CKD category is monitored every 6-12 months?

    a) G1-2

    b) G3

    c) G4

    d) G5

  • b

    Which CKD category is monitored every 4-6 months?

    a) G1-2

    b) G3

    c) G4

    d) G5

  • c

    Which CKD category is monitored every 2-4 months?

    a) G1-2

    b) G3

    c) G4

    d) G5

  • d

    Which CKD category is monitored every 1-3 months?

    a) G1-2

    b) G3

    c) G4

    d) G5

  • educate patients/improve utilization of 1st line options, address barriers to utilization of highest quality meds

    What is the role of the pharmacist in CKD care? (3)

  • NSAIDs, herbals

    Which medications should patients with CKD avoid? (2)

  • flu, hep b, pneumococcal

    Which immunizations should patients w/ CKD receive? (3)

  • progression to ESKD, proteinuria/albuminuria, CV risk

    ACEi/ARBs have been proven to reduce what? (3)